Protagonist Therapeutics, Inc. (PTGX)
After hours:
| Previous close | 25.57 |
| Open | 25.34 |
| Bid | 25.18 x 400 |
| Ask | 25.25 x 400 |
| Day's range | 25.17 - 25.75 |
| 52-week range | 13.72 - 33.34 |
| Volume | |
| Avg. volume | 693,704 |
| Market cap | 1.47B |
| Beta (5Y monthly) | 2.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.39 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 44.20 |
GlobeNewswireTurnstone Biologics Appoints William Waddill to its Board of Directors
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member o
ZacksAll You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
GuruFocus.comProtagonist Therapeutics Inc CEO Sells 25,000 Shares
Protagonist Therapeutics Inc (NASDAQ:PTGX), a biopharmaceutical company, has reported an insider sale according to a recent SEC filing.
